Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tenecteplase biosimilar - GENERIUM Pharmaceuticals

Next Previous
Search
Drug Profile

Tenecteplase biosimilar - GENERIUM Pharmaceuticals

Alternative Names: GNR-060; Metalyse biosimilar; Tenecteplase biosimilar

Latest Information Update: 11 Feb 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GENERIUM Pharmaceuticals
  • Class Anti-ischaemics; Blood coagulation factors; Cardiovascular therapies; Plasminogen activator enzymes; Serine endopeptidases; Thrombolytics
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Myocardial infarction

Most Recent Events

  • 11 Feb 2022 Phase-II/III clinical trials in Myocardial infarction in Russia (unspecified route), prior to February 2022 (GENERIUM Pharmaceuticals pipeline, February 2022)
  • 19 Dec 2019 GNR 060 is available for licensing as of 19 Dec 2019. http://www.generium.ru/en/
  • 01 Dec 2019 Phase-I clinical trials in Myocardial infarction in Russia before December 2019 (GENERIUM Pharmaceuticals pipeline, December 2019)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top